Mapping Cellular Stress Biology to Tackle Undruggable Targets
In this episode, Daniel Levine interviews Yeremiá Gizarian, co‑founder and CEO of Soleil Therapeutics, about the company’s AI‑driven platform that maps cellular stress responses to discover drugs for traditionally "undruggable" targets. The discussion explains how Soleil flips the conventional drug‑discovery paradigm by measuring thousands of live‑cell imaging features to identify phenotypic stress signatures, then deconvolutes mechanisms to select disease indications. Gizarian highlights two first‑in‑class small‑molecule candidates—SOL001 for acute myeloid leukemia and SOL002 for solid tumors—showing preclinical efficacy and a path toward IND filing by year‑end. He also outlines the platform’s broader applicability to neurodegenerative, metabolic, and other stress‑related diseases.
Is the UK Set to Become a Radiopharma Leader?
In this episode, Bruno Quinney talks with Dr. Juliana Maynard, Head of Translational Imaging at Medicines Discovery Catapult (MDC), about the rapid growth of the radiopharmaceutical sector and the UK’s strategy to become a global leader. Maynard explains how radiopharmaceuticals...
The Next Era of Healthcare Is Personal
In this episode, McKinsey’s Eric Kutcher talks with Moderna CEO Stéphane Bancel about how mRNA technology and AI are reshaping healthcare from rapid vaccine development to truly personalized medicines. Bancel explains that mRNA is an "information molecule" that can be programmed...
Beyond Senolytics: Senoadaptive Drugs & Clinical Data on GPX4 Modulation (Dr. Marco Quarta, Rubedo)
In this episode, Dr. Marco Quarta, co‑founder and CSO of Rubedo Life Sciences, discusses the company’s breakthrough first‑in‑class GPX4‑modulating drug RLS1496, which has just reported preliminary Phase 1 basket‑trial data across multiple skin indications. He explains how Rubedo’s AI‑enabled single‑cell multi‑omics...
Scaling Scientific R&D with AI Supercomputing Infrastructure — with Thomas Fuchs of Eli Lilly
In this episode, Thomas Fuchs, Chief AI Officer at Eli Lilly, explains how the company is building an AI‑ready supercomputing platform—based on NVIDIA’s DGX SuperPod B300 architecture—to accelerate drug discovery, development, and manufacturing. He highlights that the massive compute power lets...
Big Apple Exclusive: Dr. McCullough Goes Live to Unveil Potential Cancer Breakthrough
In this episode, Dr. Peter McCullough, chief scientific officer of a wellness company, discusses an observational report on the off‑label use of two generic drugs—ivermectin and mebendazole—in cancer patients. The study, now under peer review, found that nearly half of participants...
What Impact Could Protein Stabilisation Have for Cancer Patients?
In this episode of the DDW Podcast, CEO Anthony Johnson and CSO Matthew Fyfe discuss OutRun Therapeutics' novel protein‑stabilisation platform, which inhibits specific E3 ubiquitin ligases to prevent degradation of disease‑relevant proteins. Their lead program targets the E6AP ligase to...
DDW Highlights: 6 May 2026
In this episode, Bruno Quinney highlights a surge in UK biotech financing, noting £552 million ($746 million) in Q1 2026 equity funding and the UK's capture of 57% of European biotech venture capital. He also covers the UK’s sweeping clinical‑trial reforms aimed at...
Addressing Treatment Gaps in Gout
In this episode, Crystallis Therapeutics CEO James McKay explains the biology of gout, why existing urate‑lowering drugs often fail, and how the company’s next‑generation URAT1 inhibitor, detenurad, aims to close the large treatment gap for moderate‑to‑severe patients. He highlights that...
Redefining Success in Transplant Medicine
In this episode of Signals KOLs, transplant nephrologist Dr. Deirdre Sawinski, industry veteran Steve Risk (SVP Medical Affairs at Veloxys), and patient‑physician Sejal Patel discuss the stagnant long‑term outcomes in kidney transplantation despite excellent short‑term success. They highlight how current...
Psychedelics in Medicine: Curiosity & Caution
In this episode, Dr. Ryan Cole and addiction specialist Dr. Molly Rutherford discuss the surge of interest in psychedelic‑assisted therapies for conditions like addiction, PTSD, and depression, highlighting the recent presidential executive order that accelerates FDA review and funding for these...
EXPLAINER: Medicine's Forgotten Biomarker - The Homocysteine Story Your Doctor Missed
In this episode Dr. Robert Lufkin explains why homocysteine, an amino‑acid by‑product of methionine metabolism, is a powerful but overlooked risk factor for heart disease, stroke, and dementia. He reviews the biological mechanisms by which elevated homocysteine damages arterial endothelium...
343. Summary: Can This Nutrient Help Alzheimer's? - Life Extension
In this episode, Dr. Mike and Dr. Crystal discuss a recent pilot study on creatine supplementation as a potential therapy for Alzheimer's disease, featuring insights from lead author Aaron Smith. They explain how creatine, known for its role in muscle...
BREAKING: Senate Investigation Finds FDA Officials Covered-Up 25 COVID Shot Safety Signals
The episode examines a Senate investigation revealing that FDA officials allegedly suppressed about 25 statistically significant safety signals linked to COVID‑19 vaccine adverse events, including serious conditions such as Bell's palsy, cardiac failure, sudden cardiac death, and strokes. It details...
Could This Be the First Parkinson's Disease Modifier?
In this brief episode, the host and a GAIN representative discuss GT02287, a novel allosteric modulator targeting the glucocerebrosidase (GCase) enzyme, as a potential disease‑modifying therapy for Parkinson’s disease. They explain how the drug stabilizes the misfolded enzyme’s shape, enhancing...